Why Analysts Were Not Satisfied With Gilead Earnings

By Chris Lange Updated Jan 13, 5:18AM EST · Published Jul 25, 4:37PM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Why Analysts Were Not Satisfied With Gilead Earnings — © Thinkstock

Gilead Sciences Inc. (NASDAQ: GILD) reported second-quarter financial results after the markets closed on Monday. Although this is one of the world’s leading biotech companies, an earnings beat in this report was not enough to satisfy investors.

The company said that it had $3.08 in earnings per share (EPS) on $7.78 billion in revenue. There were consensus estimates from Thomson Reuters that called for $3.02 in EPS on $7.79 billion in revenue. The same period from last year had $3.15 in EPS on $8.24 billion in revenue.

As for full-year guidance, the company now expects to have revenues in the range of $29.5 billion to $30.5 billion, compared to the previous level of $30.0 billion to $31.0 billion. The consensus estimates call for $12.02 in EPS on $31.05 billion in revenue for the full year.

[nativounit]

HIV and other antiviral product sales were $3.1 billion compared to $2.7 billion for the same period in 2015 primarily due to increases in sales of our tenofovir alafenamide (TAF) based products. HCV product sales, which consist of Harvoni, Sovaldi, and Epclusa, totaled $4.0 billion versus $4.9 billion from last year.

In terms of drug sales the company reported (compared to the same period last year):

Harvoni had revenues of $2.56 billion down from $3.61 billion.
Sovaldi had revenues of $1.36 billion up from $1.29 billion.
Truvada had $942 million in revenues up from $849 million.
Atripla had revenues of $673 million down from $782 million.
Stribild had revenues of $429 million down from $447 million.
Complera/Eviplera had revenues of $368 million relatively flat from last year.
Genvoya had revenues of $302 million.
Viread had revenues of $287 million up from $271 million.

On the books, Gilead’s cash, cash equivalents and marketable securities totaled $24.6 billion at the end of this quarter, compared to $21.3 billion at the end of the first quarter. Cash flow from operating activities was $4.9 billion for the quarter. During the second quarter and the first six months of 2016, Gilead utilized $1.0 billion and $9.0 billion on stock repurchases, respectively.

Shares of Gilead closed Monday up 2.3% at $88.55, with a consensus analyst price target of $110.37 and a 52-week trading range of $77.92 to $120.37. Following the release of the earnings report, the stock was down 3.2% at $85.70 in the after-hours trading session.

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.